RADIOLABELING METHOD USING MULTIVALENT GLYCOLIGANDS AS HEPATIC RECEPTOR IMAGING AGENT

• US 20110097264A1
• Filed: 05/13/2010
• Published: 04/28/2011
• Est. Priority Date: 10/26/2009
• Status: Abandoned Application

• Current Assignee: Institute Of Nuclear Energy Research Atomic Energy Council Executive Yuan
• Original Assignee: Institute Of Nuclear Energy Research Atomic Energy Council Executive Yuan
• Inventors: Lin, Wuu-Jyh, Chien, Chuan-Yi, Yu, Hung-Man, Wang, Mei-Hui, Lee, Reiko Takasaka, Lee, Yuan-Chuan
• Application Number:
  US12/779,328
• Publication Number:
  US 20110097264A1
• Time in Patent Office: Days
• US Class Current: 424/1.69
• CPC Class Codes: A61K 51/0491 Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
• CPC Class Codes: A61K 51/0497 conjugates with a carrier being an organic compounds
• CPC Class Codes: C07F 13/005 Compounds without a metal-carbon linkage
• CPC Class Codes: C07K 1/13 Labelling of peptides

Abstract

A radiolabeling method using a multivalent glycoligand as hepatic receptor imaging agent is provided. The multivalent glycoligand-DTPA derivatives (In-111-DTPA-hexa lactoside and In-111-DTPA-tri-galactosamine glycoside) labeled with In-111 are used as hepatic receptor imaging agent. The effects of imaging of a hepatic receptor in different species are evaluated, the lowest specific radioactivity values of hepatic receptor imaging required in different species are discovered. Since the specificity of the human ASGPR closely resembles that of the mouse. This kind of radiolabelling method, agent and related study about specific radioactivity could be used in clinical trial in the future.

Claims

1. A radiolabeling method using a multivalent glycoligand as hepatic receptor imaging agent, formed by reacting a multivalent glycoligand-DTPA derivative with In-111 at room temperature or under heating for 30 min.

2. The multivalent glycoligand according to claim 1, wherein serial concentrations of the multivalent glycoligands react with a fixed amount of In-111 to get specific radioactivity of sequence In-111-DTPA-multivalent glycoligands.

3. The multivalent glycoligand according to claim 1, wherein the multivalent glycoligand is In-111-DTPA-hexa lactoside (In-111-DTPA-AHA-Asp[DCM-Lys(ah-Lac)₃]₂).

4. The multivalent glycoligand according to claim 1, wherein the multivalent glycoligand is In-111-DTPA-tri-galactosamine glycoside (In-111-DTPA-DCM-Lys(Gah-GalNAc)₃).

5. The multivalent glycoligand according to claim 3, wherein the In-111-DTPA-hexa lactoside is reacted at room temperature, the most preferred molar ratio of hexa lactoside and In-111 is 20, the labeling yield is above 99%, no addition of oxidant and purification are required in the labeling process, and the specific radioactivity is 2.5×

10¹⁰ Bq/mg.

6. The multivalent glycoligand according to claim 3, wherein the In-111-DTPA-hexa lactoside is absorbed by hepatocytes, and in presence of the same number of hepatocytes, the hepatocyte absorption in rat and mice is the same.

7. The multivalent glycoligand according to claim 3, wherein the In-111-DTPA-hexa lactoside is used to perform whole-body SPECT/CT imaging in rat and mice, in order to quantify the absorption of the In-111-DTPA-hexa lactoside per unit area, the ASGPR per unit area in rat and mice is not the same, and the ASGPR density of rat is higher than that of mice.

8. The multivalent glycoligand according to claim 4, wherein the In-111-DTPA-tri-galactosamine glycoside is reacted at a temperature higher than 90°

C., and the labeling yield is up to above 80%.

9. The multivalent glycoligand according to claim 4, wherein the specific radioactivity of the In-111-DTPA-tri-galactosamine glycoside is required to be higher than 3.4×

10⁸ Bq/mg when being used for imaging in mice, and when being used for imaging in rat, even the specific radioactivity is lower than 3.7×

10⁷ Bq/mg, a clear image is obtained.